Dr. John Cush RheumNow
5 years 11 months ago
QD Video - I'm Not Stupid (IgG4) - Lessons from the clinic. Dr. Jack Cush discusses an IgG4 case and the power of discussion https://t.co/RDIVEeyqxW
The Lancet Rheumatology TheLancetRheum
5 years 11 months ago
NEW RESEARCH: Abatacept in the treatment of diffuse cutaneous #SystemicSclerosis; clinically meaningful improvements in mRSS and other outcome measures were observed when patients transitioned to open-label #abatacept treatment https://t.co/tDSo3u8hAY #LancetRheumatology https://t.co/Nc8XYc1URW
QD Clinic - I'm Not Stupid (IgG4)
An IgG4 Case and the Power of Discussion
Dr. John Cush RheumNow
5 years 11 months ago
Congratulations to Dr. Sherine Gabriel on being elected to the National Academy of Medicine - one of the highest honors in medicine. She is president and James A. Campbell Distinguished Professor, and chief academic officer at Rush University in Chicago https://t.co/16lnBZjZWk
Dr. John Cush RheumNow
5 years 11 months ago
NEJM reports that obese pts having bariatric surgery have a longer life expectancy (less death HR 0.77; 0.68-0.87; P<0.001) than pts treated w/ nonsurgical, usual obesity care. They live 3 yrs longer (than controls) but 5 yrs shorter than gen Population https://t.co/nBa6IuKAyX
Dr. John Cush RheumNow
5 years 11 months ago
Empty out your medicine cabinets. Sat Oct 24th is DEA "TAKE BACK" day. Dispose of unused, unwanted, controlled drugs, narcotics, e-cigarettes. Theyll take your tablets, capsules, patches, pens, liquids (BUT NOT syringes, sharps, illegal drugs) Where? https://t.co/oDMYHl3mgI
A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.
Remdesivir
In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian University of Athens, and colleagues in RMD Open: Rheumatic & Musculoskeletal Diseases.
Dr. John Cush RheumNow
5 years 11 months ago
Study of seropositivity in RA patients in the RISE (43,581) registry & Marketscan pts (1185) showed ICD10 Coding with M05 had a sensitivity = 0.73- 0.76, & PPV = 0.82 -0.84 for seropositive RA. Good but does that mean Ya'll are miscoding 25% of your RA pts?https://t.co/Wc6FQeQEHA
Dr. John Cush RheumNow
5 years 11 months ago
Swedish population studied CV risk, studied gout. Among 22,057, 910 (4.1%) developed incident gout by 27.5 yrs w/ 5 Clusters: C1 no/few comorb; C2 had CKD; C3 CV dz; C4 obesity, dyslipidemia; C5 DM, HTN, diuretics. 86% of incident gout came from C1 & C4 https://t.co/TeMdXx5qU1
QD Clinic - Triage Rheumatology
What constitutes urgent, emergent and Patients you should see
Dr. John Cush RheumNow
5 years 11 months ago
Lilly has announced results of Phase 2 SERENITY trial showing the IL-23 inhibitor, mirikizumab, was more effective than PBO at week 12 (PRO and endoscopic outcomes) in moderate to severe active Crohn's disease. Efficacy continued out to week 52 https://t.co/n8Mdeonmas
Dr. John Cush RheumNow
5 years 11 months ago
SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?
Dr. John Cush RheumNow
5 years 11 months ago
Not sure why this study was done...BUT... Tociiizumab was studied in 104 hand osteoarthritis and after 12 weeks, TCZ was equivalent to Placebo in achieving100mm VAS pain reduction (-9.9 vs -7.9), but TCZ had numerically more adverse events https://t.co/NYujNQbjvm
The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.
